Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBITDA Margin (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBITDA Margin data on record, last reported at 14.02% in Q3 2025.

  • For Q3 2025, EBITDA Margin fell 1003.0% year-over-year to 14.02%; the TTM value through Sep 2025 reached 10.9%, up 4865.0%, while the annual FY2024 figure was 7.34%, 459.0% up from the prior year.
  • EBITDA Margin reached 14.02% in Q3 2025 per PLX's latest filing, up from 7.48% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 104.85% in Q4 2021 and bottomed at 142.62% in Q2 2021.
  • Average EBITDA Margin over 5 years is 23.0%, with a median of 18.24% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -13381bps in 2022, then soared 17571bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 104.85% in 2021, then plummeted by -128bps to 28.95% in 2022, then plummeted by -370bps to 136.14% in 2023, then surged by 129bps to 39.57% in 2024, then crashed by -65bps to 14.02% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 14.02% in Q3 2025, 7.48% in Q2 2025, and 40.99% in Q1 2025.